Table 3 Mixed effects model analysis of eGFR change from baseline by cumulative NSAIDs Exposure.
Years | Source | N | Estimated GFR CKD−EPI | Estimated GFR MDRD | ||
|---|---|---|---|---|---|---|
β | 95% CI | β | 95% CI | |||
3 | AMC | 1,224 | −0.005 | −0.022, 0.012 | −0.010 | −0.036, 0.017 |
SNUBH | 679 | 0.015 | −0.006, 0.036 | 0.009 | −0.026, 0.045 | |
Summary | 1,903 | 0.004 | −0.016, 0.023 | −0.003 | −0.024, 0.019 | |
6 | AMC | 1,224 | −0.007 | −0.027, 0.014 | −0.010 | −0.044, 0.023 |
SNUBH | 679 | −0.016 | −0.045, 0.012 | −0.026 | −0.074, 0.021 | |
Summary | 1,903 | −0.010 | −0.027, 0.007 | −0.016 | −0.043, 0.012 | |
9 | AMC | 1,224 | −0.001 | −0.027, 0.024 | −0.004 | −0.045, 0.038 |
SNUBH | 679 | −0.051 | −0.092, −0.011 | −0.061 | −0.127, 0.006 | |
Summary | 1,903 | −0.024 | −0.072, 0.025 | −0.026 | −0.080, 0.029 | |
12 | AMC | 1,224 | 0.014 | −0.017, 0.046 | 0.048 | −0.002, 0.099 |
SNUBH | 679 | −0.025 | −0.104, 0.054 | 0.035 | −0.095, 0.165 | |
Summary | 1,903 | 0.009 | −0.020, 0.038 | 0.046 | −0.001, 0.093 | |
15 | AMC | 1,224 | 0.002 | −0.043, 0.046 | 0.002 | −0.070, 0.074 |
SNUBH | 679 | −0.076 | −0.206, 0.054 | −0.186 | −0.399, 0.027 | |
Summary | 1,903 | −0.012 | −0.070, 0.046 | −0.064 | −0.240, 0.112 | |
18 | AMC | 1,224 | −0.089 | −0.159, −0.019 | −0.096 | −0.208, 0.017 |
